JP2022514597A5 - - Google Patents

Info

Publication number
JP2022514597A5
JP2022514597A5 JP2021535272A JP2021535272A JP2022514597A5 JP 2022514597 A5 JP2022514597 A5 JP 2022514597A5 JP 2021535272 A JP2021535272 A JP 2021535272A JP 2021535272 A JP2021535272 A JP 2021535272A JP 2022514597 A5 JP2022514597 A5 JP 2022514597A5
Authority
JP
Japan
Prior art keywords
salts
composition according
aqueous solution
solution composition
divalent metal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021535272A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022514597A (ja
Filing date
Publication date
Priority claimed from GBGB1821149.0A external-priority patent/GB201821149D0/en
Priority claimed from GBGB1911581.5A external-priority patent/GB201911581D0/en
Application filed filed Critical
Priority claimed from PCT/GB2019/053654 external-priority patent/WO2020128506A1/en
Publication of JP2022514597A publication Critical patent/JP2022514597A/ja
Publication of JP2022514597A5 publication Critical patent/JP2022514597A5/ja
Pending legal-status Critical Current

Links

JP2021535272A 2018-12-21 2019-12-20 新規組成物 Pending JP2022514597A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1821149.0A GB201821149D0 (en) 2018-12-21 2018-12-21 Novel composition
GB1821149.0 2018-12-21
GB1911581.5 2019-08-13
GBGB1911581.5A GB201911581D0 (en) 2019-08-13 2019-08-13 Novel composition
PCT/GB2019/053654 WO2020128506A1 (en) 2018-12-21 2019-12-20 Novel composition

Publications (2)

Publication Number Publication Date
JP2022514597A JP2022514597A (ja) 2022-02-14
JP2022514597A5 true JP2022514597A5 (https=) 2022-12-21

Family

ID=69104798

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021535273A Active JP7421556B2 (ja) 2018-12-21 2019-12-20 新規組成物
JP2021535272A Pending JP2022514597A (ja) 2018-12-21 2019-12-20 新規組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021535273A Active JP7421556B2 (ja) 2018-12-21 2019-12-20 新規組成物

Country Status (9)

Country Link
US (2) US12239685B2 (https=)
EP (2) EP3897573A1 (https=)
JP (2) JP7421556B2 (https=)
KR (1) KR20210114000A (https=)
CN (2) CN113301885A (https=)
AU (1) AU2019411551A1 (https=)
BR (1) BR112021011753A2 (https=)
CA (1) CA3124529A1 (https=)
WO (2) WO2020128507A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12239685B2 (en) 2018-12-21 2025-03-04 Arecor Limited Composition
WO2020229369A1 (en) * 2019-05-10 2020-11-19 Xellia Pharmaceuticals Aps Daptomycin aqueous formulations
EP4117625A1 (en) 2020-03-12 2023-01-18 Baxter International Inc. Daptomycin formulations containing a combination of sorbitol and mannitol
CN116726145A (zh) * 2022-03-04 2023-09-12 海南普利制药股份有限公司 一种稳定的酯肽类药物组合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696412B1 (en) * 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
US6716962B2 (en) 2000-07-17 2004-04-06 Micrologix Biotech Inc. Extractive purification of lipopeptide antibiotics
WO2002059145A1 (en) 2000-12-18 2002-08-01 Cubist Pharmaceuticals, Inc. Methods for preparing purified lipopeptides
IL156394A0 (en) 2000-12-18 2004-01-04 Cubist Pharm Inc Methods for preparing purified lipopeptides
US20060014674A1 (en) * 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
CN100421726C (zh) 2006-03-06 2008-10-01 南京凯瑞尔纳米生物技术有限公司 包含有肽类药物的纳米复合物滴眼液及其制备方法
WO2011035108A1 (en) 2009-09-17 2011-03-24 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
WO2011062676A1 (en) 2009-11-23 2011-05-26 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
US20170348382A1 (en) * 2014-12-16 2017-12-07 Dr. Reddy's Laboratories Limited Lyophilized injectable compositions of daptomycin
WO2018073269A1 (en) * 2016-10-21 2018-04-26 Xellia Pharmaceuticals Aps Liquid formulations of daptomycin
RU2770366C2 (ru) * 2017-08-31 2022-04-15 Кселлия Фармасьютикалз Апс Препараты даптомицина
US12239685B2 (en) 2018-12-21 2025-03-04 Arecor Limited Composition
WO2020229369A1 (en) 2019-05-10 2020-11-19 Xellia Pharmaceuticals Aps Daptomycin aqueous formulations

Similar Documents

Publication Publication Date Title
JP2022514597A5 (https=)
JP2015525762A5 (https=)
JP2015527402A5 (https=)
NZ602685A (en) Concentrated protein formulations and uses thereof
JP2010529999A5 (https=)
HRP20241526T1 (hr) Stabilni višedozni pripravci, koji sadrže protutijelo i konzervans
JP2013545745A5 (https=)
JP2017002035A5 (https=)
HRP20180514T1 (hr) Kontinuirana primjena l-dopa, inhibitora dopa dekarboksilaze, inhibitora katekol-o-metiltransferaze i sastava za isto
JP2009531457A5 (https=)
JP2019081811A5 (https=)
JP2019504086A5 (https=)
JP2017535616A5 (https=)
RU2016135952A (ru) Композиции ингибитора дофа-декарбоксилазы
RU2013156999A (ru) Композиции для ухода за полостью рта, содержащие фитиновую кислоту
JP2017507973A5 (https=)
WO2004017998A3 (en) Topical emulsion- gel composition comprising diclofenac sodium
JP2022514858A5 (https=)
RU2006107446A (ru) Водный фармацевтический раствор, содержащий оксиметазолин и/или ксилометазолин
FI2034956T4 (fi) Matalan viskositeetin omaavia glykosaminoglykaaneja käsittäviä koostumuksia ja mainitun koostumuksen käyttö kroonisen kystiitin terapiassa
RU2017106159A (ru) Состав фактора viii
JP2019533679A5 (https=)
RU2019119405A (ru) Лиофилизированные фармацевтические композиции далбаванцина
JP2013518808A5 (https=)
JP2007501817A5 (https=)